Oragenics Concludes Neurological Asset Purchase: Unveiling a Promising Horizon in Drug Development for Brain Injuries

Oragenics has completed the earlier disclosed purchase of assets centred on neurological pharmaceutical treatments from Odyssey Health. 

This strategic initiative involves obtaining a concussion product, ONP-002, a wholly synthetic neurosteroid that is in the developmental stages of addressing mild traumatic brain injury. 

The deal encompasses Odyssey’s complete ownership and stakes in ONP-001, a neurosteroid in progress for the management of Niemann-Pick Type-C condition. 

The corporation will retain the remaining holdings and operations of Odyssey subsequent to the procurement of the neurological assets. 

Kim Murphy, the head executive at Oragenics, commented, “Our decision to invest in this innovative therapy is driven by our commitment to pioneering solutions that build upon our expertise in intranasal drug delivery and our dedication to improving patient outcomes.” 

Murphy went on to add, “These new pipeline candidates hold potential to deliver innovative treatments for millions affected by mTBI and NPC and introduce Oragenics into a market that is projected to grow to $8.9bn annually by 2027.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.